Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-03-2004 | Original Article

^99mTc-EDDA/HYNIC-TOC and ¹⁸F-FDG in thyroid cancer patients with negative ¹³¹I whole-body scans

Authors: Michael Gabriel, Franz Froehlich, Clemens Decristoforo, Christian Ensinger, Eveline Donnemiller, Elisabeth von Guggenberg, Dirk Heute, Roy Moncayo

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2004

Abstract

Several studies have reported on the expression of somatostatin receptors in patients with differentiated thyroid cancer (DTC). The aim of this study was to evaluate the imaging abilities of a recently developed technetium-99m labelled somatostatin analogue, ^99mTc-EDDA/HYNIC-TOC (^99mTc-TOC), in terms of precise localisation of disease. The study population comprised 54 patients (24 men, 30 women; age range 22–90 years) with histologically confirmed DTC who presented with recurrent or persistent disease as indicated by elevated Tg levels after initial treatment. All patients were negative on the iodine-131 post-therapy whole-body scans. Fluorine-18 fluorodeoxyglucose positron emission tomography (¹⁸F-FDG PET) was performed in a subgroup of 36 patients. The study population consisted of two groups: Group A (n=22) comprised patients with disease recurrence as shown by elevated Tg levels but without detectable pathology. In group B (n=32), pre-existing lesions were known. Among the 54 cases, SSTR scintigraphy was true positive in 33 (61.1%), true negative in 4 (7.4%) and false negative in 17 (31.5%) cases, which resulted in a sensitivity of 66%. A total of 138 tumour foci were localised in 33 patients. The fraction of true positive ^99mTc-TOC findings was positively correlated (P<0.01) with elevated Tg levels (higher than 30 ng/ml). Despite two false positive findings, analysis on a lesion basis demonstrated better diagnostic efficacy with ¹⁸F-FDG PET (P<0.001); however, it also revealed substantial agreement between the imaging techniques [Cohen’s kappa of 0.62 (0.47–0.78)]. In conclusion, scintigraphy with ^99mTc-TOC might be a promising tool for treatment planning; it is easy to perform and showed sufficient accuracy for localisation diagnostics in thyroid cancer patients with recurrent or metastatic disease.

Pacini F, DeGroot LJ. Thyroid neoplasia. In: DeGroot LJ, Jameson JL, eds. Endocrinology, 4th edn. Philadelphia: Saunders; 2001:1541–1566.

Ronga G, Fiorentino A, Paserio E, et al. Can iodine-131 whole-body scan be replaced by thyroglobulin measurement in the post surgical follow-up of differentiated thyroid carcinoma. J Nucl Med 1990; 31:1766–1771.PubMed

Ozata M, Suzuki S, Miyamoto T, Tsuan Liu RT, Fierro-Renoy F, Degroot LJ. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 1994; 79:98–105.PubMed

Lubin E, Mechli-Frish S, Zatz S, et al. Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma. J Nucl Med 1994; 35:257–262.PubMed

Schlumberger MJ. Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status. J Endocrinol Invest 1999; 22 (11 Suppl):3–7.

Feine U, Lietzenmayer R, Hanke JP, Held J, Woehrle H, Mueller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996; 37:1468–1472.PubMed

Schlueter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative¹³¹I scan. J Nucl Med 2001; 42:71–76.

Helal BO, Merlet P, Toubert ME, et al. Clinical impact of¹⁸F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative ¹³¹I scanning results after therapy. J Nucl Med 2001; 42:1464–1469.PubMed

Briele B, Hotze A, Kroopp J, et al. A comparison of²⁰¹Tl and ^99mTc-MIBI in the follow-up of differentiated thyroid carcinomas. Nuklearmedizin 1991; 30:115–124.PubMed

10.

Lind P, Gallowitsch HJ, Langsteger W, Kresnik E, Mikosch P, Gomez I. Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma. J Nucl Med 1997; 38:348–354.PubMed

11.

Miyamoto S, Kasagi K, Misaki T, Alam MS, Konishi J. Evaluation of technetium-99m-MIBI scintigraphy in metastatic differentiated thyroid carcinoma. J Nucl Med 1997; 38:352–356.PubMed

12.

Rubello D, Mazzarotte R, Casara D. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery. Eur J Nucl Med 2000; 27:431–440.PubMed

13.

Ng DCE, Sundram FX, Sin AE.^99mTc-sestamibi and ¹³¹I whole-body scintigraphy and initial serum thyroglobulin in the management of differentiated thyroid carcinoma. J Nucl Med 2000; 41:631–635.PubMed

14.

Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111-In-DTPA-d-Phe] and [123-I-Tyr]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20:716–731.PubMed

15.

Krenning EP, Kwekkeboom DJ, de Jong M, et al. Essentials of peptide receptor scintigraphy with emphasis on somatostatin analog octreotide. Semin Oncol 1994; 21 (Suppl 13):6–14.

16.

Lamberts SWJ, Reubi JC, Krenning EP. Somatostatin and the concept of peptide receptor scintigraphy in oncology. Semin Oncol 1994; 21 (Suppl) 13:1–5.

17.

Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000; 41:1704–1713.PubMed

18.

Balon HR, Goldsmith SJ, Siegel BA, et al. Procedure guidelines for somatostatin receptor scintigraphy with¹¹¹In-pentetreotide. J Nucl Med 2001; 42:1134–1138.PubMed

19.

Tenenbaum F, Lumbroso J, Schlumberger M, Caillou B, Fragu P, Parmentier C. Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma. J Nucl Med 1995; 36:807–810.PubMed

20.

Baudin E, Schlumberger M, Lumbroso J, Travagli JP, Caillou B, Parmentier C. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioidine scan. J Clin Endocrinol Metab 1996; 81:2541–2544.

21.

Ahlman H, Tisell LE, Wangberg B, et al. The relevance of somatostatin receptors in thyroid neoplasia. Yale J Biol Med 1997; 70:523–533.PubMed

22.

Gulec SA, Serafini AN, Sridhar KS, et al. Somatostatin receptor expression in Hürthle cell cancer of the thyroid. J Nucl Med 1998; 39:243–245.PubMed

23.

Garin E, Devillers A, Le Cloirec J, et al. Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake. Eur J Nucl Med 1998; 25:687–694.CrossRefPubMed

24.

Kolby L, Wangberg B, Ahlman H, et al. Somatostatin receptor subtypes, octreotide scintigraphy, and clinical response to octreotide treatment in patients with neuroendocrine tumors. World J Surg 1998; 22:679–683.CrossRefPubMed

25.

Valli N, Catargi B, Ronci N, et al. Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy. Thyroid 1999; 9:583–589.PubMed

26.

Haslinghuis LM, Krenning EP, De Herder WW, Reijs AE, Kwekkeboom DJ. Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest 2001; 24:415–422.

27.

Goerges R, Kahaly G, Mueller-Brand J, Maecke H, Roser HW, Bockisch A. Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. Thyroid 2001; 11:647–659.CrossRefPubMed

28.

Forssell-Aronsson EB, Nilsson O, Benjegard A, et al.¹¹¹In-DTPA-d-Phe¹-octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med 2000; 41:636–642.PubMed

29.

Decristoforo C, Melendez-Alafort L, Sosabowski JK, Mather SJ.^99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with ¹¹¹In-octreotide. J Nucl Med 2000; 41:1114–1119.PubMed

30.

Decristoforo C, Mather SJ, Cholewinski W, Donnemiller E, Riccabona G, Moncayo R.^99mTc-EDDA/HYNIC-TOC: a new ^99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours: first clinical results and intra-patient comparison with ¹¹¹In-labelled octreotide derivates. Eur J Nucl Med 2000; 27:1318–1325.PubMed

31.

Gabriel M, Decristoforo C, Donnemiller E, et al. An intrapatient comparison of^99mTc-EDDA/HYNIC-TOC with ¹¹¹In-DTPA-octreotide for diagnosis of somatostatin receptor expressing tumors. J Nucl Med 2003; 44:708–716.PubMed

32.

Sobin LH, Wittekind C. International Union Against Cancer. TNM classification of malignant tumours, 5th edn. New York: Wiley-Liss, 1997.

33.

American Joint Committee on Cancer. AJCC cancer staging manual, 5th edn. In: Part II: 8. Thyroid Gland. Philadelphia, New York: Lippincott-Raven; 1997:59–61.

34.

Decristoforo C, Mather SJ. Preparation,^99mTc-labelling and in vitro characterisation of HYNIC and N₃S modified RC-160 and [Tyr³]-octreotide. Bioconjug Chem 1999; 10:431–438.PubMed

35.

Le Rest C, Bomanji JB, Costa DC, Townsend CE, Visvikis D, Ell PJ. Functional imaging of malignant paragangliomas and carcinoid tumours. Eur J Nucl Med 2001; 28:478–482.CrossRefPubMed

36.

Petrich T, Boerner AR, Otto D, Hofmann M, Knapp WH. Influence of rhTSH on [¹⁸F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2002; 29:641–647.CrossRefPubMed

37.

Wang W, Larson SM, Tuttle RM, et al. Resistance of [¹⁸F]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 2001; 11:1169–1175.PubMed

38.

Robbins RJ, Hill RH, Wang W, Macapinlac HH, Larson SM. Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue. Thyroid 2000; 10:177–183.PubMed

39.

Arnold R, Simon B, Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion 2000; 62 Suppl 1:84–91.

40.

Waldherr C, Schumacher T, Pless M, et al. Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using [⁹⁰Y]-DOTA-d-Phe¹-Tyr³-octreotide: a pilot study. Nucl Med Commun 2001; 22:673–678.CrossRefPubMed

41.

Hsu CH, Liu FY, Yen RF, Kao CH. Tc-99m MIBI SPECT in detecting metastatic papillary thyroid carcinoma in patients with elevated human serum thyroglobulin levels but negative I-131 whole body scan. Endocr Res 2003; 29:9–15.CrossRefPubMed

42.

Rubello D, Piotto A, Pagetta C, Pelizzo MR, Casara D.^99mTc-MIBI radio-guided surgery for recurrent thyroid carcinoma: technical feasibility and procedure, and preliminary clinical results. Eur J Nucl Med Mol Imaging 2002; 29:1201–1205.CrossRefPubMed

Title: 99mTc-EDDA/HYNIC-TOC and 18F-FDG in thyroid cancer patients with negative 131I whole-body scans
Authors: Michael Gabriel
Franz Froehlich
Clemens Decristoforo
Christian Ensinger
Eveline Donnemiller
Elisabeth von Guggenberg
Dirk Heute
Roy Moncayo
Publication date: 01-03-2004
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2004
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-003-1376-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

^99mTc-EDDA/HYNIC-TOC and ¹⁸F-FDG in thyroid cancer patients with negative ¹³¹I whole-body scans

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2004

March 2004

Diagnosis of neuroendocrine tumours by retrospective image fusion: is there a benefit?

Effects of photon attenuation on the determination of cardiac volumes from reconstructed counts in gated blood pool SPET

Highlights of the Annual Congress of the European Association of Nuclear Medicine, Amsterdam 2003

Kinetics of [11C]choline uptake in prostate cancer: a PET stydy

The prefrontal cortex: insights from functional neuroimaging using cognitive activation tasks